Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 18 May 2017

Xbrane Biopharma releases interim report for the period January - March 2017

Xbrane Biopharma AB    

Published: 08:00 CEST 18-05-2017 /GlobeNewswire /Source: Xbrane Biopharma AB / : XBRANE /ISIN: SE0007789409

Xbrane Biopharma releases interim report for the period January - March 2017

Press release



Xbrane  Biopharma  ABs  interim report for the period January - March 2017 is now available on the Company's website, www.xbrane.com.


Period January - March

  • Net sales SEK 6,840 thousand (854)
  • Total income SEK 6,980 thousand (861)
  • Earnings before tax SEK -10,134 thousand (-5,530)
  • Cash flow from current operations SEK -9,353 thousand (-7,556)
  • Earnings per share before dilution SEK -2.19 (-2.48)


Significant events during the period

  • Xbrane received GMP certificate for the Spherotide production facility in Italy from AIFA (Italian Medicines Agency).
  • Xbrane delivered its first batch of Spherotide to a value of SEK 7 million to its partner in the Middle East.
  • Xbrane reported positive comparative pre-clinical data on Xlucane.


Significant events after the period

  • Xbrane reported positive comparative in vivo effect data on Spherotide.
  • Xbrane recruits Susanna Helgesen as new CFO / Head of Investor Relations.


About Xbrane

Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.



For further information, please contact:

Martin Åmark

Chief Executive Officer

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com


Susanna Helgesen


M: +46 (0) 708-278 636

E: susanna.helgesen@xbrane.com


This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 May 18 2017.

Xbrane interim report Q1 2017
Press release - Xbrane Biopharma publish interim report for Q1 2017

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Xbrane Biopharma AB, Stureplan 15, Stockholm 111 45, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.